Last reviewed · How we verify

NCT03156153

A Study of Bumetanide for the Treatment of Autism Spectrum Disorders

Completed Phase 2 Last updated 1 March 2021
What this trial tests

Phase 2 trial testing Bumetanide in Autism Spectrum Disorder in 120 participants. Completed in 10 July 2019.

Timeline
24 May 2017
Primary endpoint
8 July 2019
10 July 2019

Quick facts

Lead sponsorXinhua Hospital, Shanghai Jiao Tong University School of Medicine
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment120
Start date24 May 2017
Primary completion8 July 2019
Estimated completion10 July 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

Adults 3 to 6, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators are going to carry out a randomized double-blind placebo-controlled trial to study the efficiency and mechanism of bumetanide on the treatment of children with Autism Spectrum Disorder.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications.
    Jiang CC, Lin LS, Long S, Ke XY, et al · · 2022 · cited 157× · PMID 35817793 · DOI 10.1038/s41392-022-01081-0
  2. How Staying Negative Is Good for the (Adult) Brain: Maintaining Chloride Homeostasis and the GABA-Shift in Neurological Disorders.
    Hui KK, Chater TE, Goda Y, Tanaka M. · · 2022 · cited 16× · PMID 35875665 · DOI 10.3389/fnmol.2022.893111
  3. The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder.
    Li Q, Zhang L, Shan H, Yu J, et al · · 2022 · cited 10× · PMID 35660740 · DOI 10.1038/s41398-022-01987-x
  4. Contribution of Monocarboxylate Transporter 6 to the Pharmacokinetics and Pharmacodynamics of Bumetanide in Mice.
    Jones RS, Ruszaj D, Parker MD, Morris ME. · · 2020 · cited 3× · PMID 32587098 · DOI 10.1124/dmd.120.000068

Verify or expand the search:

Other trials of Bumetanide

Trials testing the same drug.

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03156153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing